Latest news with #JohnRim
Korea Herald
6 days ago
- Business
- Korea Herald
Samsung Biologics reports second quarter 2025 financial results
INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025. "Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and President of Samsung Biologics. "With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence." SECOND QUARTER 2025 RESULTS Samsung Biologics posted consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion in the second quarter of 2025. On a standalone basis, the company reported revenue of KRW 1,014.2 billion and operating profit of KRW 477.0 billion. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4. In the first half of 2025, standalone revenue surpassed KRW 2 trillion, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached USD 2.4 billion, bringing up the cumulative value to USD 18.7 billion. BUSINESS UPDATES In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients' manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards. The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making. In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry's greater demands to ultimately maximize corporate value and sustainable growth potential. On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility. About Samsung Biologics Samsung Biologics (KRX: is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.
![[Bio USA] Samsung Biologics doubles down on CDMO leadership after biosimilar spinoff](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.21e8febe0361403eb6fc8a1d8bf30695_T1.jpg&w=3840&q=100)
Korea Herald
18-06-2025
- Business
- Korea Herald
[Bio USA] Samsung Biologics doubles down on CDMO leadership after biosimilar spinoff
CEO John Rim says Bioepis separation unlocks transparency, enhances investor clarity, sharpens strategic focus BOSTON — Samsung Biologics CEO John Rim unveiled an ambitious road map to strengthen the company's position as a global leader in CDMO during a press conference held on the sidelines of this year's Bio USA on Tuesday, emphasizing sharpened focus, expanded capabilities and accelerated global expansion. At the center of the announcement was Samsung Biologics' recent corporate split, which fully separates its CDMO operations from Samsung Bioepis, its former biosimilar arm. Rim described the move as a milestone that allows Samsung Biologics to operate as a 'pure-play CDMO.' 'By becoming a stand-alone CDMO, we can focus entirely on our core mission—delivering best-in-class biomanufacturing and development services while enhancing transparency and trust with our global partners,' said Rim. 'This also enables investors to evaluate each business based on its own strategic value and growth potential.' The strategic restructuring is expected to unlock hidden value within Samsung's portfolio and further elevate shareholder value by making the distinct business models more visible and investable. Highlighting strong sector fundamentals, Rim pointed to rising global demand for biologics manufacturing, driven by expanding indications for blockbuster drugs and the development of new modalities, such as ADCs, AOCs and gene therapies. "Following the corporate split, our overseas clients responded positively, as it eliminated any perceived conflicts of interest," Rim emphasized. "Samsung Biologics will continue to fuel its growth by advancing its three core pillars: Geographic expansion, increased capacity and diversification of modalities." According to market research firm Frost & Sullivan, the global biologics CDMO market is projected to grow at a CAGR of 15 percent from $21.8 billion in 2024 to $43.9 billion in 2029. Despite some pharma companies announcing in-house capacity expansions, CMO outsourcing demand continues to rise as pharma remains cautious with internal investments. "Just three years ago, there were industry-wide concerns about potential oversupply in the CDMO market. However, we've since witnessed consistent double-digit growth, and with continued category expansion — particularly in the antibody segment — the outlook for CDMOs appears stronger than ever," Rim explained. Samsung Biologics is doubling down on its global client outreach. The company currently serves 17 of the top 20 global pharmaceutical companies and has intensified efforts to expand its reach among the top 40. In addition to sales offices in New Jersey and Boston, it opened a Tokyo office earlier this year to improve engagement with Asia-based clients. 'Our global clients trust Samsung for both scale and speed. As we expand geographically and technologically, we are committed to offering localized support with global excellence,' Rim emphasized. As of June 2025, Samsung Biologics has secured five new contracts this year totaling 3.35 trillion won ($2.58 billion), surpassing 60 percent of last year's full-year bookings of 5.4 trillion won. The company's cumulative order value since inception now stands at $18.7 billion. 'Despite macroeconomic uncertainties, our pipeline remains strong, and we maintain our full-year revenue guidance of 20–25 percent growth,' said Rim. 'We expect to see continued momentum as we deepen global partnerships and reinforce our role as a full-service biopharma enabler.' Meanwhile, Samsung Biologics is investing heavily in modality diversification to meet evolving customer needs. It recently launched a dedicated facility for ADCs, supporting full development and GMP production, with capabilities ranging from 2 milliliters to 500 liters. The company plans to introduce a dedicated ADC DP line by Q1 2027, completing an end-to-end solution within its Songdo site in Incheon. 'The more competitors there are, the more positive impact it has on patients, so we fully welcome competition. Of course, when it comes to winning contracts, we believe we possess the best internal competitiveness. We are confident that not only our infrastructure but also the strength of our workforce are our greatest assets.'
Korea Herald
16-06-2025
- Business
- Korea Herald
Samsung Biologics launches organoid platform to boost early-stage drug discovery
South Korea's leading contract development and manufacturing organization, Samsung Biologics, announced Monday the launch of Samsung Organoids, a cutting-edge drug screening service designed to support corporate clients throughout drug discovery and development. Organoids are three-dimensional cell culture systems engineered to closely replicate the structure and function of human organs. Due to their high physiological relevance, organoids are rapidly emerging as a next-generation research model in drug development. They offer clinically meaningful insights into drug responses, making them valuable tools for lead compound selection, biomarker discovery and efficacy prediction. 'The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine,' said John Rim, CEO and president of Samsung Biologics. 'The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis.' Samsung Organoids will enable precision screening to predict patient-specific drug responses, streamline preclinical development and accelerate timelines for investigational new drug filings. The platform uses data-driven analysis to assess the characteristics and mechanisms of drug candidates, offering multi-modal insights that enhance decision-making. Through the expansion, Samsung Biologics broadens its service portfolio to include preclinical research, covering the full spectrum from target discovery and lead identification to preclinical studies and clinical trial planning. By leveraging its expertise in drug development and manufacturing, the company aims to help clients overcome early-stage development hurdles and improve clinical outcomes.
Korea Herald
22-05-2025
- Business
- Korea Herald
Samsung Biologics splits biosimilar business to boost CDMO, investment flexibility
Spin-off aims to sharpen operational focus, build client trust, enhance shareholder value Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into a new holding company, separating them from its contract development and manufacturing organization business to sharpen the strategic focus of each unit. Through the structural realignment, Samsung Biologics will concentrate solely on its CDMO business, while the newly created holding company, tentatively called Samsung Epis Holdings, will oversee the biosimilar unit Samsung Bioepis. Kim Kyung-ah, CEO of Samsung Bioepis, will concurrently serve as CEO of the new holding company. Samsung Bioepis was established in 2012 as a joint venture between Samsung Biologics and US-based Biogen, with Samsung initially holding an 85 percent stake. In 2022, Samsung Biologics acquired Biogen's remaining shares for $2.3 billion. 'This split reflects our decision to enhance competitiveness by responding swiftly to global changes and sharpening strategic focus,' said Samsung Biologics CEO John Rim. 'Both entities will accelerate their growth and are well-positioned to establish themselves as global leaders in biopharma.' Samsung Biologics clarified that the creation of Samsung Epis Holdings through the spin-off bears no relation to the governance structure of Samsung Group. The separation also aims to address concerns from CDMO clients regarding the in-house biosimilar unit. The dual-track model had raised conflict-of-interest concerns, particularly related to potential technology leakage. 'We've invested significant time and resources to ease these concerns, yet it's realistically difficult to eliminate all worries across our client base,' said Ryu Seung-ho, executive vice president of Samsung Biologics, at a press conference on Thursday. 'This restructuring will further allow each business to be properly valued in the market and give shareholders more flexibility to invest based on their own strategies," he added. Under the deal, shareholders will receive shares in both companies based on current book values — approximately 0.65 shares in Samsung Biologics and 0.35 shares in Samsung Epis Holdings for each share held. With the restructuring expected to fuel focused growth, both entities have outlined distinct long-term goals. Samsung Biologics will double down on its ambition to become a global top-tier CDMO by investing in three key areas: expanding production capacity, diversifying its service portfolio, and widening its international footprint. New initiatives will target next-generation biomanufacturing technologies, including antibody-drug conjugates or ADCs, adeno-associated viruses or AAVs, and pre-filled syringes. Samsung Epis Holdings will focus on expanding Samsung Bioepis's biosimilar portfolio to over 20 products, while also developing platform technologies and exploring investment opportunities in emerging technologies and global markets. 'Samsung Epis Holdings plans to establish new subsidiaries in addition to managing the existing Samsung Bioepis,' said Kim Hyoung-joon, vice president of Samsung Bioepis, at the press conference. 'These new entities will focus on developing platform technologies for future growth. We also aim to generate revenue through investments in domestic and global companies,' he added. Regarding the upcoming procedures, the company will submit a registration statement on July 29, followed by a shareholder meeting for approval on Sept. 16. Upon completion of the spin-off, effective Oct. 1, Samsung Epis Holdings will make Samsung Bioepis its wholly owned subsidiary. Both Samsung Biologics and Samsung Epis Holdings are scheduled to be relisted on Oct. 29. Trading of Samsung Biologics shares will be temporarily suspended from Sept. 29 through Oct. 28.
Korea Herald
28-04-2025
- Business
- Korea Herald
Samsung Biologics boosts contract wins with $513m US deal
Samsung Biologics, the biotech arm of Samsung Group, has secured its second contract manufacturing deal this year, signing a major agreement worth 737.3 billion won ($513 million) with a US-based pharmaceutical company. In a regulatory filing Monday, the company said the new contract with the undisclosed partner will run through the end of 2031. The deal is equivalent to 16.2 percent of Samsung Biologics' revenue in 2024. This latest win follows Samsung Biologics' largest-ever contract manufacturing agreement, a 2.07 trillion won deal signed in January with a European pharmaceutical firm. With the two deals combined, Samsung Biologics' total cumulative contracts for the year have reached 2.8 trillion won, accounting for more than 50 percent of last year's total deal value of 5.4 trillion won. The company's total annual contract volume last year was driven by three major deals, each valued at over 1 trillion won. Samsung Biologics now counts 17 of the world's top 20 pharmaceutical companies as clients. Last year, on a consolidated basis, the company posted record sales of 4.54 trillion won, up 23 percent from the previous year, while operating profit rose 19 percent to 1.32 trillion won. For the first quarter of this year, Samsung Biologics' operating profit more than doubled to 486.7 billion won, compared to 221.3 billion won a year earlier, while sales rose 37.1 percent to 1.29 trillion won. 'We sustained solid momentum in the first quarter, supported by the efficient operations across all our plants and continued partnerships with our clients,' said CEO John Rim. To meet the growing demand for biologics, Samsung Biologics has been expanding its production capacity. The company currently operates five production plants in Songdo, Incheon, and plans to expand to eight by 2032, targeting a combined production capacity of around 1.32 million liters. Starting this month, it began operations at its fifth plant, bringing its total capacity to 784,000 liters — the largest biomanufacturing capacity in the world. 'The launch of the fifth plant and our dedicated antibody-drug conjugate facility marks another milestone in expanding our capacity to cater to diverse client demands,' Rim said, explaining the company's commitment to delivering long-term value for clients and shareholders through strategic investments in technology. Samsung Biologics plans to continue bolstering its contract pipeline throughout the year. While operating a dedicated facility for antibody-drug conjugates as part of its strategic move into the next-generation cancer therapeutics market, the company also recently opened a sales office in Japan, adding to its existing locations in New Jersey and Boston to strengthen relationships across key global markets.
